The high costs of infliximab in the initial management of steroid-refractory acute severe ulcerative colitis (ASUC) are largely offset with the savings from avoiding hospitalisation and procedure-related costs. And the equation should only improve in favour of anti-TNF therapy with the growing uptake of biosimilars, a Victorian research team said. Their study of 118 patients ...
Costs support infliximab as first-line salvage therapy.
By Mardi Chapman
28 Feb 2019